グルタミンは,KRASが調節する代謝経路を通じて,臓がんの成長を促進する
Jaekyoung Son1, Costas A Lyssiotis, Haoqiang Ying
1Division of Genomic Stability and DNA Repair, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
Nature
|March 29, 2013
まとめ
臓がん細胞は,成長のためにグルタミン,アスパルテート,オックスロアセテートを含むユニークな代謝経路を利用します. この経路を阻害すると,腫瘍の進行が止まり,臓管内腺がんの新たな治療戦略の可能性が生まれます.
科学分野:
- バイオケミストリー バイオケミストリー
- 腫瘍学 腫瘍学
- メタボリック経路は
背景:
- 癌細胞は,正常細胞と比較して,異なった代謝依存性を示す.
- グルタミン (Glutamine) は,多くの腫瘍におけるアナボリックプロセスを供給する重要なアミノ酸です.
- ガンにおけるグルタミン代謝の理解は,標的治療の開発に不可欠です.
研究 の 目的:
- 臓管内腺がん (PDAC) の新型グルタミン代謝経路の特定と特徴付け.
- PDAC腫瘍の成長と生存におけるこの経路の役割を調査する.
- この非正規のグルタミン代謝を標的とした治療の可能性を探求する.
主な方法:
- ヒト管腺がん (PDAC) 細胞系を使用した.
- 酵素分析と遺伝的阻害によるグルタミン代謝の調査.
- 経路操作後の腫瘍の成長を in vitro および in vivo で評価した.
- この代謝再プログラミングの調節における腫瘍性KRASの役割を分析した.
主要な成果:
- PDAC細胞がグルタミン由来アスパルテートを細胞質の中でオキシロアセテートに変換する非正規の経路を特定しました.
- この経路は,NADPH/NADP ((+) の比率を増加させ,細胞の酸化還元状態を維持し,活性酸素種を減少させます.
- グルタミン欠乏または経路酵素の遺伝的阻害により酸化ストレスが増加し,グルタチオンは減少しました.
- 鍵となる酵素のノックダウンにより,PDACの成長がインビトロおよびインビボで抑制された.
- 腫瘍性KRASは,酵素の転写制御を通じて,この代謝の再プログラミングを媒介する.
結論:
- PDAC細胞は,固有のミトコンドリア経路とは異なる,グルタミン代謝のためのユニークな細胞プラズマ経路に依存しています.
- この経路は,PDACの成長,酸化還元バランス,生存に不可欠です.
- このKRAS媒介の代謝的脆弱性をターゲットにすることは,臓がんに対する有望な治療戦略です.
さらに関連する動画
関連する概念動画
Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...


